×
About 12,150 results

ALLMedicine™ Pulmonary Arterial Hypertension Center

Research & Reviews  4,162 results

Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of V...
https://doi.org/10.1165/rcmb.2021-0332OC
American Journal of Respiratory Cell and Molecular Biology; Le Vely B, Phan C et. al.

May 14th, 2022 - Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by the dysfunction of pulmonary endothelial cells (ECs) and obstructive vascular remodeling. The non-receptor tyrosine kinase c-Abelson (cAbl) plays central rol...

Comment on: Nailfold microvascular abnormalities are associated with a higher prevalenc...
https://doi.org/10.1093/rheumatology/keac291
Rheumatology (Oxford, England); Katsumasa O, Matsuda S et. al.

May 14th, 2022 - Comment on: Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.|2022|Katsumasa O,Matsuda S,Kotani T,Takeuchi T,|

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
https://clinicaltrials.gov/ct2/show/NCT01730092

May 13th, 2022 - Introduction: Pulmonary arterial hypertension (PAH) is a rare disorder associated with poor survival. Endothelial dysfunction resulting from 1) genetic susceptibility, and 2) a triggering stimulus that initiates pulmonary vascular injury, the two-...

Reversed Potts Shunt Outcome in Suprasystemic Pulmonary Arterial Hypertension: A System...
https://doi.org/10.2174/1573403X18666220509203335
Current Cardiology Reviews; Mendel B, Christianto et. al.

May 12th, 2022 - Reversed Potts shunt has been a prospective approach to treat suprasystemic pulmonary hypertension, particularly when medication treatment fails to reduce right ventricular afterload. This meta-analysis aims to review the clinical, laboratory, and...

see more →

Guidelines  3 results

Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmona...
https://doi.org/10.1016/j.cjca.2019.11.041
The Canadian Journal of Cardiology; Hirani N, Brunner NW et. al.

Jul 20th, 2020 - The landscape of pulmonary hypertension (PH) has changed significantly since the last Canadian Cardiovascular Society/Canadian Thoracic Society position statement in 2005. Since then, advances in our understanding of the pathophysiology of PH and ...

Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline an...
https://doi.org/10.1016/j.chest.2018.11.030
Chest Klinger JR, Elliott CG et. al.

Jan 21st, 2019 - Pulmonary arterial hypertension (PAH) carries a poor prognosis if not promptly diagnosed and appropriately treated. The development and approval of 14 medications over the last several decades have led to a rapidly evolving approach to therapy, an...

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications
https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12633
Fundamental & Clinical Pharmacology; Ala M, .

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

see more →

Drugs  164 results see all →

Clinicaltrials.gov  200 results

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
https://clinicaltrials.gov/ct2/show/NCT01730092

May 13th, 2022 - Introduction: Pulmonary arterial hypertension (PAH) is a rare disorder associated with poor survival. Endothelial dysfunction resulting from 1) genetic susceptibility, and 2) a triggering stimulus that initiates pulmonary vascular injury, the two-...

Dapagliflozin in Pulmonary Arterial Hypertension
https://clinicaltrials.gov/ct2/show/NCT05179356

May 12th, 2022 - The objective of this study is to evaluate the effects of oral dapagliflozin (Forxiga®) treatment versus placebo in clinically stable patients with PAH on background vasodilator combination therapy on cardio-pulmonary exercise capacity, pulmonary ...

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure i...
https://clinicaltrials.gov/ct2/show/NCT04813926

May 11th, 2022 - Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that carry blood from the heart to the lungs. PAH occurs when the openings in the blood vessels of the lungs get smaller and smaller. These smaller openings can...

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
https://clinicaltrials.gov/ct2/show/NCT04039464

May 11th, 2022 - A Phase III, randomized, open label, pragmatic trial to compare the safety and efficacy of first-line combination therapy (sildenafil and bosentan) to first-line monotherapy (sildenafil alone) in pediatric subjects with WHO Functional Classes II o...

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
https://clinicaltrials.gov/ct2/show/NCT02932410

Apr 27th, 2022 - This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial ...

see more →

News  329 results

PAH care turns corner with new therapies, intensified monitoring
https://www.mdedge.com/chestphysician/article/251541/pulmonology/pah-care-turns-corner-new-therapies-intensified-monitoring
Christine Kilgore, MDedge News

Feb 8th, 2022 - Aggressive up-front combination therapy, more lofty treatment goals, and earlier and more frequent reassessments to guide treatment are improving care of patients with pulmonary arterial hypertension (PAH) while at the same time making it more com.

Heart Transplant After Severe COVID; Patients Stuck With HVAD; ICH Triggers
https://www.medpagetoday.com/cardiology/prevention/96331

Dec 21st, 2021 - A Brazilian man successfully received a heart transplant while still hospitalized with severe COVID-19 illness. (U.S. News) People with secondary prevention implantable cardioverter-defibrillators had appropriate shocks happen rarely after 3 month...

Mental Stress-Induced CV Events; Telling Retina Scans; Bedtime and Heart Health
https://www.medpagetoday.com/cardiology/prevention/95549

Nov 9th, 2021 - Theories abound regarding the mechanism behind the link between mRNA vaccines and myocarditis. (Wall Street Journal) Registry data show that COVID-19 patients with ischemic heart disease were not at a disadvantage in survival, whereas those with h...

Ulcer on the Leg
https://www.mdedge.com/dermatology/article/248220/mixed-topics/ulcer-leg
Joana Cruañes-Monferrer, MD, Eduardo Alias-Carrascosa, MD

Nov 3rd, 2021 - The Diagnosis: Calcinosis Cutis Due to Systemic Sclerosis Sine Scleroderma Laboratory evaluation was notable for high titers of antinuclear antibodies (>1/320; reference range, 0–1/80) and positive anticentromere antibodies. There were no other re.

FDA Probes LAAO; Dairy Fat's Heart Benefit; Repatha OK'd for Pediatric HeFH
https://www.medpagetoday.com/cardiology/prevention/94751

Sep 28th, 2021 - In response to a study published in August, FDA is investigating whether women really have worse outcomes after Watchman left atrial appendage occlusion (LAAO) than men. Shorter intervals between measurements: a way to slice a minute off standard ...

see more →

Patient Education  2 results see all →